A 48-month Open Label Multi-centered Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 in Patients With Parkinson's Disease With "Wearing Off" Motor Fluctuations and "on" Period Dyskinesias
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Perampanel (Primary)
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors Eisai Inc
- 12 Feb 2013 Planned number of patients changed to 225.
- 11 Feb 2013 New trial record